1
|
Komori T, Yoneda N, Kozaka K, Ohno N, Takata N, Seki A, Yoshimura K, Ikeda H, Harada K, Kobayashi S. Two cases of perivenous hepatic iron deposition in the background of alcoholic liver cirrhosis. Abdom Radiol (NY) 2025; 50:1600-1605. [PMID: 39395043 PMCID: PMC11947072 DOI: 10.1007/s00261-024-04624-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2024] [Revised: 09/27/2024] [Accepted: 10/02/2024] [Indexed: 10/14/2024]
Affiliation(s)
- Takahiro Komori
- Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
| | - Norihide Yoneda
- Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Kazuto Kozaka
- Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Naoki Ohno
- Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Noboru Takata
- Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Akihiro Seki
- Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Kaori Yoshimura
- Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Hiroko Ikeda
- Department of Pathology Kanazawa University Hospital, Kanazawa, Japan
| | - Kenichi Harada
- Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Satoshi Kobayashi
- Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| |
Collapse
|
2
|
Schwarz M, Schmidbauer VU, Malik J, Nowak NM, Kienast P, Watzenboeck M, Stuempflen M, Schwarz C, Kittinger J, Bettelheim D, Haberl C, Binder J, Kiss H, Reiberger T, Prayer D, Kasprian G. Intrauterine blood transfusion causes dose- and time-dependent signal alterations in the liver and the spleen on fetal magnetic resonance imaging. Eur Radiol 2025; 35:1605-1614. [PMID: 39663265 PMCID: PMC11836162 DOI: 10.1007/s00330-024-11228-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2024] [Accepted: 10/21/2024] [Indexed: 12/13/2024]
Abstract
BACKGROUND Intrauterine transfusions (IUTs) are a life-saving treatment for fetal anemia. However, with each transfusion, iron bypasses uptake regulation through the placenta and accumulates in fetal organs. Unlike other imaging modalities, fetal magnetic resonance imaging (MRI) is capable of non-invasively assessing fetal liver disease and/or organ iron overload. This study aimed to investigate the effects of IUTs on MRI findings in the fetal liver and spleen. STUDY DESIGN For this retrospective study, we included eight fetuses undergoing IUT and prenatal MRI from 2014 to 2023. The fetuses were gestational age-matched with a cohort that received fetal MRI for other indications, but no IUTs. Signal intensity (SI) and volumetric analyses of the liver and the spleen were performed. RESULTS Fetuses receiving transfusions had significantly larger volumes of both liver (p = 0.003) and spleen (p = 0.029). T1 SI inversely correlated with the number of IUTs (Pearson's r = -0.43, p = 0.099). This effect regressed over time (r = 0.69, p = 0.057). T2 SI did not correlate significantly with transfusion frequency but showed a strong positive correlation with the number of days between IUT and MRI (r = 0.91, p = 0.002). For splenic SI measures, similar effects were observed regarding T1 SI reduction per received transfusion (r = -0.36, p = 0.167) and recovery of T2 SI after IUT (r = 0.88, p = 0.004). CONCLUSION This is the first study to report the effects of IUTs on MRI data of fetal livers and spleens. We observed considerable dose- and time-dependent SI alterations of the liver and spleen following IUT. Furthermore, fetal hepatosplenomegaly can be expected following IUT. KEY POINTS Question What fetal changes are found by MRI after life-saving intrauterine transfusion (IUT)? Findings Dose- and time-dependent reductions in signal intensity of the fetal liver and spleen, as well as hepatosplenomegaly, were found after intrauterine transfusion. Clinical relevance Intrauterine transfusions cause transient iron overload with consequential changes in MRI signal intensity of fetal livers and spleens. Fetal hepatosplenomegaly can be expected following transfusions. Radiologists' awareness of changes following IUT may improve report quality.
Collapse
Affiliation(s)
- Michael Schwarz
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
| | - Victor Ulrich Schmidbauer
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
| | - Jakob Malik
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Nikolaus Michael Nowak
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Patric Kienast
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Martin Watzenboeck
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Marlene Stuempflen
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Caroline Schwarz
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
| | - Jakob Kittinger
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Dieter Bettelheim
- Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria
| | - Christina Haberl
- Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria
| | - Julia Binder
- Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria
| | - Herbert Kiss
- Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria
| | - Thomas Reiberger
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
| | - Daniela Prayer
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Gregor Kasprian
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
3
|
Tipirneni-Sajja A, Shrestha U, Esparza J, Morin CE, Kannengiesser S, Roberts NT, Peeters JM, Sharma SD, Hu HH. State-of-the-Art Quantification of Liver Iron With MRI-Vendor Implementation and Available Tools. J Magn Reson Imaging 2025; 61:1110-1132. [PMID: 39133767 DOI: 10.1002/jmri.29526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2024] [Revised: 06/19/2024] [Accepted: 06/20/2024] [Indexed: 01/06/2025] Open
Abstract
The role of MRI to estimate liver iron concentration (LIC) for identifying patients with iron overload and guiding the titration of chelation therapy is increasingly established for routine clinical practice. However, the existence of multiple MRI-based LIC quantification techniques limits standardization and widespread clinical adoption. In this article, we review the existing and widely accepted MRI-based LIC estimation methods at 1.5 T and 3 T: signal intensity ratio (SIR) and relaxometry (R2 and R2*) and discuss the basic principles, acquisition and analysis protocols, and MRI-LIC calibrations for each technique. Further, we provide an up-to-date information on MRI vendor implementations and available offline commercial and free software for each MRI-based LIC quantification approach. We also briefly review the emerging and advanced MRI techniques for LIC estimation and their current limitations for clinical use. Lastly, we discuss the implications of MRI-based LIC measurements on clinical use and decision-making in the management of patients with iron overload. Some of the key highlights from this review are as follows: 1) Both R2 and R2* can estimate accurate and reproducible LIC, when validated acquisition parameters and analysis protocols are applied, 2) Although the Ferriscan R2 method has been widely used, recent consensus and guidelines endorse R2*-MRI as the most accurate and reproducible method for LIC estimation, 3) Ongoing efforts aim to establish R2*-MRI as the standard approach for quantifying LIC, and 4) Emerging R2*-MRI techniques employ radial sampling strategies and offer improved motion compensation and broader dynamic range for LIC estimation. EVIDENCE LEVEL: 1 TECHNICAL EFFICACY: Stage 2.
Collapse
Affiliation(s)
- Aaryani Tipirneni-Sajja
- Department of Biomedical Engineering, The University of Memphis, Memphis, Tennessee, USA
- Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Utsav Shrestha
- Department of Biomedical Engineering, The University of Memphis, Memphis, Tennessee, USA
- Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Juan Esparza
- Department of Biomedical Engineering, The University of Memphis, Memphis, Tennessee, USA
| | - Cara E Morin
- Department of Radiology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA
- Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | | | - Nathan T Roberts
- MR Clinical Solutions & Research Collaborations, GE HealthCare, Waukesha, Wisconsin, USA
| | | | - Samir D Sharma
- Canon Medical Research USA, Inc., Mayfield Village, Ohio, USA
| | - Houchun H Hu
- Radiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| |
Collapse
|
4
|
Kemp JM, Ghosh A, Dillman JR, Krishnasarma R, Manhard MK, Tipirneni-Sajja A, Shrestha U, Trout AT, Morin CE. Practical approach to quantitative liver and pancreas MRI in children. Pediatr Radiol 2025; 55:36-57. [PMID: 39760887 DOI: 10.1007/s00247-024-06133-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2024] [Revised: 11/29/2024] [Accepted: 12/03/2024] [Indexed: 01/07/2025]
Abstract
Quantitative abdominal magnetic resonance imaging (MRI) offers non-invasive, objective assessment of diseases in the liver, pancreas, and other organs and is increasingly being used in the pediatric population. Certain quantitative MRI techniques, such as liver proton density fat fraction (PDFF), R2* mapping, and MR elastography, are already in wide clinical use. Other techniques, such as liver T1 mapping and pancreas quantitative imaging methods, are emerging and show promise for enhancing diagnostic sensitivity and treatment monitoring. Quantitative imaging techniques have historically required a breath-hold, making them more difficult to implement in the pediatric population. However, technological advances, including free-breathing techniques and compressed sensing imaging, are making these techniques easier to implement. The purpose of this article is to review current liver and pancreas quantitative techniques and to provide a practical guide for implementing these techniques in pediatric practice. Future directions of liver and pancreas quantitative imaging will be briefly discussed.
Collapse
Affiliation(s)
- Justine M Kemp
- Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
- Department of Radiology, University of Cincinnati College of Medicine, 3188 Bellevue Avenue, Cincinnati, OH, 45219, USA.
| | - Adarsh Ghosh
- Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA
| | - Jonathan R Dillman
- Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA
- Department of Radiology, University of Cincinnati College of Medicine, 3188 Bellevue Avenue, Cincinnati, OH, 45219, USA
| | - Rekha Krishnasarma
- Department of Radiology and Radiological Sciences, Monroe Carell Jr. Children's Hospital, Vanderbilt University Medical Center, 2200 Children's Way, Nashville, TN, 37232, USA
| | - Mary Kate Manhard
- Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA
- Department of Radiology, University of Cincinnati College of Medicine, 3188 Bellevue Avenue, Cincinnati, OH, 45219, USA
| | - Aaryani Tipirneni-Sajja
- Department of Biomedical Engineering, The University of Memphis, Memphis, TN, USA
- Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Utsav Shrestha
- Department of Biomedical Engineering, The University of Memphis, Memphis, TN, USA
- Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Andrew T Trout
- Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA
- Department of Radiology, University of Cincinnati College of Medicine, 3188 Bellevue Avenue, Cincinnati, OH, 45219, USA
| | - Cara E Morin
- Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
- Department of Radiology, University of Cincinnati College of Medicine, 3188 Bellevue Avenue, Cincinnati, OH, 45219, USA.
| |
Collapse
|
5
|
Ning X, Peng F, Tan S, Tang C, Luo C, Xiao F, Zhao C, Peng P. Quantitative MRI evaluation of iron deposition in patients with transfusion-dependent thalassemia: clinical management insights. Expert Rev Hematol 2024; 17:977-983. [PMID: 39625161 DOI: 10.1080/17474086.2024.2435353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2024] [Accepted: 11/01/2024] [Indexed: 12/07/2024]
Abstract
BACKGROUND In patients with thalassemia, different organs are affected differently by iron overload. Nevertheless, the reasons for this could be the same key transporters. This study investigated the iron deposition in different organs of transfusion-dependent thalassemia (TDT) patients and its correlation. RESEARCH DESIGN AND METHODS This cross-sectional study involved 54 TDT patients who underwent MRI T2* examinations of the heart, liver, pancreas, spleen, kidneys, and pituitary. The study analyzed the iron deposition in each organ and evaluated the correlation of iron deposition using Spearman's test. RESULTS Among the 54 patients with TDT, liver iron overload was found in 49/54 (90.7%) cases, pancreas iron overload in 43/54 (79.6%) cases, spleen iron overload in 18/26 (69.2%) patients, heart iron overload in 20/54 (37.0%) cases, and kidney iron overload in 8/54 (14.8%) patients. Most patients (66.7%) with iron overload in the liver but not in the heart exhibited spleen iron abnormalities. Pituitary T2* and pancreas T2* (r = 0.790), pituitary T2* and kidney T2* (r = 0.692), kidney T2* and pancreas T2* (r = 0.672) showed positive correlation (all p < 0.05). CONCLUSIONS Patients with TDT exhibited significant organ-specific iron overload. These findings highlight the importance of routine MRI screening for monitoring and managing iron overload in patients with TDT. Pituitary, pancreas, and kidney may have similar iron-loading mechanisms.
Collapse
Affiliation(s)
- Xiaojing Ning
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Fei Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Siyu Tan
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Cheng Tang
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
- NHC Key Laboratory, Thalassemia Medicine (Guangxi Medical University), Nanning, Guangxi Zhuang Autonomous Region, China
| | - Chaotian Luo
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Fangyan Xiao
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Chen Zhao
- MR Research Collaboration, Siemens Healthineers Ltd, Guangzhou, China
| | - Peng Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
- NHC Key Laboratory, Thalassemia Medicine (Guangxi Medical University), Nanning, Guangxi Zhuang Autonomous Region, China
| |
Collapse
|
6
|
Feng Q, Yi J, Li T, Liang B, Xu F, Peng P. Narrative review of magnetic resonance imaging in quantifying liver iron load. Front Med (Lausanne) 2024; 11:1321513. [PMID: 38362538 PMCID: PMC10867177 DOI: 10.3389/fmed.2024.1321513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2023] [Accepted: 01/18/2024] [Indexed: 02/17/2024] Open
Abstract
Objective To summarize the research progress of magnetic resonance imaging (MRI) in quantifying liver iron load. Methods To summarize the current status and progress of MRI technology in the quantitative study of liver iron load through reviewing the relevant literature at home and abroad. Results Different MRI sequence examination techniques have formed a series of non-invasive methods for the examination of liver iron load. These techniques have important clinical significance in the imaging diagnosis of liver iron load. So far, the main MRI methods used to assess liver iron load are: signal intensity measurement method (signal intensity, SI) [signal intensity ratio (SIR) and difference in in-phase and out-of-phase signal intensity], T2/R2 measurement (such as FerriScan technique), ultra-short echo time (UTE) imaging technique, and susceptibility weighted imaging (including conventional susceptibility weighted imaging) (SWI), quantitative susceptibility mapping (QSM), T2*/R2* measurement, Dixon and its derivative techniques. Conclusion MRI has become the first choice for the non-invasive examination of liver iron overload, and it is helpful to improve the early detection of liver injury, liver fibrosis, liver cirrhosis and liver cancer caused by liver iron overload.
Collapse
Affiliation(s)
- Qing Feng
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
| | - Jixing Yi
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
| | - Tao Li
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
| | - Bumin Liang
- School of International Education, Guangxi Medical University, Nanning, China
| | - Fengming Xu
- Department of Radiology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers' Hospital, Liuzhou, China
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Peng Peng
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| |
Collapse
|
7
|
Ringe KI, Wang J, Deng Y, Pi S, Geahchan A, Taouli B, Bashir MR. Abbreviated MRI Protocols in the Abdomen and Pelvis. J Magn Reson Imaging 2024; 59:58-69. [PMID: 37144673 DOI: 10.1002/jmri.28764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 04/13/2023] [Accepted: 04/13/2023] [Indexed: 05/06/2023] Open
Abstract
Abbreviated MRI (AMRI) protocols rely on the acquisition of a limited number of sequences tailored to a specific question. The main objective of AMRI protocols is to reduce exam duration and costs, while maintaining an acceptable diagnostic performance. AMRI is of increasing interest in the radiology community; however, challenges limiting clinical adoption remain. In this review, we will address main abdominal and pelvic applications of AMRI in the liver, pancreas, kidney, and prostate, including diagnostic performance, pitfalls, limitations, and cost effectiveness will also be discussed. Level of Evidence: 3 Technical Efficacy Stage: 3.
Collapse
Affiliation(s)
- Kristina I Ringe
- Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany
| | - Jin Wang
- Department of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
| | - Ying Deng
- Department of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
| | - Shan Pi
- Department of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
| | - Amine Geahchan
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Bachir Taouli
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Mustafa R Bashir
- Department of Radiology, Center for Advanced Magnetic Resonance Development, Duke University Medical Center, Durham, North Carolina, USA
- Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
| |
Collapse
|
8
|
Marti-Aguado D, Ten-Esteve A, Baracaldo-Silva CM, Crespo A, Coello E, Merino-Murgui V, Fernandez-Paton M, Alfaro-Cervello C, Sánchez-Martín A, Bauza M, Jimenez-Pastor A, Perez-Girbes A, Benlloch S, Pérez-Rojas J, Puglia V, Ferrández A, Aguilera V, Latorre M, Monton C, Escudero-García D, Bosch-Roig I, Alberich-Bayarri Á, Marti-Bonmati L. Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease. Front Endocrinol (Lausanne) 2023; 14:1213441. [PMID: 37600695 PMCID: PMC10436077 DOI: 10.3389/fendo.2023.1213441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 07/18/2023] [Indexed: 08/22/2023] Open
Abstract
Objective To assess the prevalence of pancreatic steatosis and iron overload in non-alcoholic fatty liver disease (NAFLD) and their correlation with liver histology severity and the risk of cardiometabolic diseases. Method A prospective, multicenter study including NAFLD patients with biopsy and paired Magnetic Resonance Imaging (MRI) was performed. Liver biopsies were evaluated according to NASH Clinical Research Network, hepatic iron storages were scored, and digital pathology quantified the tissue proportionate areas of fat and iron. MRI-biomarkers of fat fraction (PDFF) and iron accumulation (R2*) were obtained from the liver and pancreas. Different metabolic traits were evaluated, cardiovascular disease (CVD) risk was estimated with the atherosclerotic CVD score, and the severity of iron metabolism alteration was determined by grading metabolic hiperferritinemia (MHF). Associations between CVD, histology and MRI were investigated. Results In total, 324 patients were included. MRI-determined pancreatic iron overload and moderate-to severe steatosis were present in 45% and 25%, respectively. Liver and pancreatic MRI-biomarkers showed a weak correlation (r=0.32 for PDFF, r=0.17 for R2*). Pancreatic PDFF increased with hepatic histologic steatosis grades and NASH diagnosis (p<0.001). Prevalence of pancreatic steatosis and iron overload increased with the number of metabolic traits (p<0.001). Liver R2* significantly correlated with MHF (AUC=0.77 [0.72-0.82]). MRI-determined pancreatic steatosis (OR=3.15 [1.63-6.09]), and iron overload (OR=2.39 [1.32-4.37]) were independently associated with high-risk CVD. Histologic diagnosis of NASH and advanced fibrosis were also associated with high-risk CVD. Conclusion Pancreatic steatosis and iron overload could be of utility in clinical decision-making and prognostication of NAFLD.
Collapse
Affiliation(s)
- David Marti-Aguado
- Digestive Disease Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
- Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Valencia, Spain
| | - Amadeo Ten-Esteve
- Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Valencia, Spain
- Department of Technologies for Health and Well-Being, Polytechnic University of Valencia, Valencia, Spain
| | | | - Ana Crespo
- Digestive Disease Department, Hospital Arnau de Vilanova, Valencia, Spain
| | - Elena Coello
- Hepatology and Liver Transplantation Unit, La Fe University and Polytechnic Hospital, Valencia, Spain
| | - Víctor Merino-Murgui
- Digestive Disease Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
| | - Matias Fernandez-Paton
- Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Valencia, Spain
| | - Clara Alfaro-Cervello
- Pathology Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
- Faculty of Medicine, University of Valencia, Valencia, Spain
| | - Alba Sánchez-Martín
- Pathology Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
| | - Mónica Bauza
- Pathology Department, La Fe University and Polytechnic Hospital, Valencia, Spain
| | - Ana Jimenez-Pastor
- Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Valencia, Spain
- Quantitative Imaging Biomarkers in Medicine, QUIBIM SL, Valencia, Spain
| | | | - Salvador Benlloch
- Digestive Disease Department, Hospital Arnau de Vilanova, Valencia, Spain
- CIBERehd, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain
| | - Judith Pérez-Rojas
- Pathology Department, La Fe University and Polytechnic Hospital, Valencia, Spain
| | - Víctor Puglia
- Pathology Department, Hospital Arnau de Vilanova, Valencia, Spain
| | - Antonio Ferrández
- Pathology Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
- Faculty of Medicine, University of Valencia, Valencia, Spain
| | - Victoria Aguilera
- Hepatology and Liver Transplantation Unit, La Fe University and Polytechnic Hospital, Valencia, Spain
- CIBERehd, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain
| | - Mercedes Latorre
- Hepatology Unit, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
| | - Cristina Monton
- Digestive Disease Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
| | - Desamparados Escudero-García
- Digestive Disease Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
- Faculty of Medicine, University of Valencia, Valencia, Spain
| | - Ignacio Bosch-Roig
- Universitat Politècnica de València, Institute of Telecommunications and Multimedia Applications (iTEAM), Valencia, Spain
| | - Ángel Alberich-Bayarri
- Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Valencia, Spain
- Quantitative Imaging Biomarkers in Medicine, QUIBIM SL, Valencia, Spain
| | - Luis Marti-Bonmati
- Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Valencia, Spain
- Radiology Department, La Fe University and Polytechnic Hospital, Valencia, Spain
| |
Collapse
|
9
|
Plaikner M, Lanser L, Kremser C, Weiss G, Henninger B. 1.5-T MR relaxometry in quantifying splenic and pancreatic iron: retrospective comparison of a commercial 3D-Dixon sequence and an established 2D multi-gradient echo sequence. Eur Radiol 2023; 33:4973-4980. [PMID: 36800012 PMCID: PMC10289981 DOI: 10.1007/s00330-023-09451-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 01/16/2023] [Accepted: 01/18/2023] [Indexed: 02/18/2023]
Abstract
OBJECTIVES To compare the quantitative measurement of splenic and pancreatic iron content using a commercial 3D-Dixon sequence (qDixon) versus an established fat-saturated R2* relaxometry method (ME-GRE). METHODS We analyzed splenic and pancreatic iron levels in 143 MR examinations (1.5 T) using the qDixon and a ME-GRE sequence (108 patients: 65 males, 43 females, mean age 61.31 years). Splenic and pancreatic R2* values were compared between both methods using Bland-Altman plots, concordance correlation coefficients (CCC), and linear regression analyses. Iron overload (R2* > 50 1/s) was defined for both organs and compared using contingency tables, overall agreement, and Gwet's AC1 coefficient. RESULTS Of all analyzable examinations, the median splenic R2* using the qDixon sequence was 25.75 1/s (range: 5.6-433) and for the ME-GRE sequence 35.35 1/s (range: 10.9-400.8) respectively. Concerning the pancreas, a median R2* of 29.93 1/s (range: 14-111.45) for the qDixon and 31.25 1/s (range: 14-97) for the ME-GRE sequence was found. Bland-Altman analysis showed a mean R2* difference of 2.12 1/s with a CCC of 0.934 for the spleen and of 0.29 1/s with a CCC of 0.714 for the pancreas. Linear regression for the spleen/pancreas resulted in a correlation coefficient of 0.94 (p < 0.001)/0.725 (p < 0.001). Concerning iron overload, the proportion of overall agreement between the two methods was 91.43% for the spleen and 93.18% for the pancreas. CONCLUSIONS Our data show good concordance between R2* values obtained with a commercial qDixon sequence and a validated ME-GRE relaxometry method. The 3D-qDixon sequence, originally intended for liver assessment, seems to be a reliable tool for non-invasive evaluation of iron content also in the spleen and the pancreas. KEY POINTS • A 3D chemical shift imaging sequence and 2D multi-gradient echo sequence show good conformity quantifying splenic and pancreatic R2* values. • The 3D chemical shift imaging sequence allows a reliable analysis also of splenic and pancreatic iron status. • In addition to the liver, the analysis of the spleen and pancreas is often helpful for further differential diagnostic clarification and patient guidance regarding the iron status.
Collapse
Affiliation(s)
- Michaela Plaikner
- Department of Radiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - Lukas Lanser
- Department of Internal Medicine, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - Christian Kremser
- Department of Radiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
| | - Günter Weiss
- Department of Internal Medicine, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - Benjamin Henninger
- Department of Radiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| |
Collapse
|
10
|
Ghahremani GG, Hahn ME, Fishman EK. Computed tomography of hyper-attenuated liver: Pictorial essay. Clin Imaging 2023; 97:1-6. [PMID: 36857928 DOI: 10.1016/j.clinimag.2023.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 02/07/2023] [Accepted: 02/20/2023] [Indexed: 02/25/2023]
Abstract
Demonstration of a very dense or hyper-attenuated liver on the pre-contrast CT images of the abdomen can be an unexpected finding. It may present as a diagnostic challenge if the underlying cause of it is not apparent from the provided clinical history. There are about 12 different pathologic conditions that are associated with deposition of radiopaque elements within the hepatic parenchyma, resulting in diffuse or multi-lobar hyperdense appearance of the liver on abdominal radiographs and CT. Most of them are drug-induced or iatrogenic in nature, while others are the sequelae of genetic disorders like thalassemia, Wilson's disease, and primary hemochromatosis. This pictorial essay will present the CT appearance and etiology of hyper-attenuated liver in various clinical entities.
Collapse
Affiliation(s)
- Gary G Ghahremani
- Department of Radiology, University of California-San Diego Medical Center, 200 West Arbor Drive, San Diego, CA 92103, USA.
| | - Michael E Hahn
- Department of Radiology, University of California-San Diego Medical Center, 200 West Arbor Drive, San Diego, CA 92103, USA
| | - Elliot K Fishman
- Department of Radiology, Johns Hopkins University Hospital, 733 North Broadway, Baltimore, MD 21205, USA
| |
Collapse
|
11
|
Updates on Quantitative MRI of Diffuse Liver Disease: A Narrative Review. BIOMED RESEARCH INTERNATIONAL 2022; 2022:1147111. [PMID: 36619303 PMCID: PMC9812615 DOI: 10.1155/2022/1147111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 12/10/2022] [Accepted: 12/12/2022] [Indexed: 12/29/2022]
Abstract
Diffuse liver diseases are highly prevalent conditions around the world, including pathological liver changes that occur when hepatocytes are damaged and liver function declines, often leading to a chronic condition. In the last years, Magnetic Resonance Imaging (MRI) is reaching an important role in the study of diffuse liver diseases moving from qualitative to quantitative assessment of liver parenchyma. In fact, this can allow noninvasive accurate and standardized assessment of diffuse liver diseases and can represent a concrete alternative to biopsy which represents the current reference standard. MRI approach already tested for other pathologies include diffusion-weighted imaging (DWI) and radiomics, able to quantify different aspects of diffuse liver disease. New emerging MRI quantitative methods include MR elastography (MRE) for the quantification of the hepatic stiffness in cirrhotic patients, dedicated gradient multiecho sequences for the assessment of hepatic fat storage, and iron overload. Thus, the aim of this review is to give an overview of the technical principles and clinical application of new quantitative MRI techniques for the evaluation of diffuse liver disease.
Collapse
|
12
|
Chae YJ, Heo H, Woo CW, Kim ST, Kwon JI, Choi MY, Sung YS, Kim KW, Kim JK, Choi Y, Woo DC. Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects. J Clin Transl Hepatol 2022; 10:1167-1175. [PMID: 36381105 PMCID: PMC9634766 DOI: 10.14218/jcth.2021.00499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 02/09/2022] [Accepted: 03/17/2022] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND AND AIMS Efficacy evaluations with preclinical magnetic resonance imaging (MRI) are uncommon, but MRI in the preclinical phase of drug development provides information that is useful for longitudinal monitoring. The study aim was to monitor the protective effectiveness of silymarin with multiparameter MRI and biomarkers in a thioacetamide (TAA)-induced model of liver injury in rats. Correlation analysis was conducted to assess compare the monitoring of liver function by MRI and biomarkers. METHODS TAA was injected three times a week for 8 weeks to generate a disease model (TAA group). In the TAA and silymarin-treated (TAA-SY) groups, silymarin was administered three times weekly from week 4. MR images were acquired at 0, 2, 4, 6, and 8 weeks in the control, TAA, and TAA-SY groups. RESULTS The area under the curve to maximum time (AUCtmax) and T2* values of the TAA group decreased over the study period, but the serological markers of liver abnormality increased significantly more than those in the control group. In the TAA-SY group, MRI and serological biomarkers indicated attenuation of liver function as in the TAA group. However, pattern changes were observed from week 6 to comparable levels in the control group with silymarin treatment. Negative correlations between either AUCtmax or T2* values and the serological biomarkers were observed. CONCLUSIONS Silymarin had hepatoprotective effects on TAA-induced liver injury and demonstrated the usefulness of multiparametric MRI to evaluate efficacy in preclinical studies of liver drug development.
Collapse
Affiliation(s)
- Yeon Ji Chae
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Hwon Heo
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Chul-Woong Woo
- Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
| | - Sang-Tae Kim
- Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
| | - Jae-Im Kwon
- Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
| | - Monica Young Choi
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Yu Sub Sung
- Clinical Research Center, Asan Medical Center, Seoul, Republic of Korea
| | - Kyung Won Kim
- Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Jeong Kon Kim
- Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Yoonseok Choi
- Medical Research Institute, Gangneung Asan Hospital, Gangneung-si, Gangwon-do, Republic of Korea
- Correspondence to: Dong Cheol Woo, Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. ORCID: https://orcid.org/0000-0001-8202-015X. Tel: +82-2-3010-4155, Fax: +82-10-5559-7102, E-mail: ; Yoonseok Choi, Medical Research Institute, Gangneung Asan Hospital, University of Ulsan College of Medicine 38, Bangdong-gil, Sacheon-myeon, Gangneung-si, Gangwon-do 25440, Korea. ORCID: https://orcid.org/0000-0002-8478-2999. Tel: +82-33-610-4799, Fax: +82-33-610-3089, E-mail:
| | - Dong-Cheol Woo
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
- Correspondence to: Dong Cheol Woo, Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. ORCID: https://orcid.org/0000-0001-8202-015X. Tel: +82-2-3010-4155, Fax: +82-10-5559-7102, E-mail: ; Yoonseok Choi, Medical Research Institute, Gangneung Asan Hospital, University of Ulsan College of Medicine 38, Bangdong-gil, Sacheon-myeon, Gangneung-si, Gangwon-do 25440, Korea. ORCID: https://orcid.org/0000-0002-8478-2999. Tel: +82-33-610-4799, Fax: +82-33-610-3089, E-mail:
| |
Collapse
|
13
|
Zhang J, Liu K, Sun Y, Yu J. Magnetic resonance spectroscopy for quantification of liver iron deposition in hereditary hemochromatosis of a Chinese family: Four case reports. Medicine (Baltimore) 2022; 101:e31742. [PMID: 36401425 PMCID: PMC9678622 DOI: 10.1097/md.0000000000031742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
RATIONALE Hereditary hemochromatosis (HH) is a major cause of liver iron overload. The gold standard for the diagnosis of liver iron overload is the histopathological analysis of a liver sample collected by biopsy. The biopsy procedure is both invasive and painful and carries some risks of complications. The multi-echo single-voxel magnetic resonance spectroscopy (HISTO) technique can be used for noninvasive, quantitative assessment of liver iron overload. PATIENT CONCERNS We report 4 Chinese Han men, who were relatives. Patient A was admitted with diabetes and presented with thrombocytopenia and skin hyperpigmentation. The other patients had no specific clinical presentation. DIAGNOSES Patient A was suspected of having iron in the liver on routine magnetic resonance imaging, therefore, further HISTO, laboratory testing, and liver biopsy were performed, which confirmed iron metabolic abnormalities. Furthermore, we identified hepatic iron deposition using HISTO and laboratory testing of his son and 2 brothers. Combined with symptoms, auxiliary examinations, and liver biopsy, HH was considered. INTERVENTIONS As the 4 patients had no other discomfort other than patient A who had diabetes, patient A was placed on therapy comprising the insulin pump, acarbose, and platelet booster capsule. OUTCOMES After treatment, the diabetic symptoms of patient A improved. The patient and his relatives were regularly followed-up for HH. LESSONS HH should be considered when hepatic iron deposition is suspected by routine magnetic resonance, as the HISTO sequence can quantitate liver iron deposition and leads to a promising diagnosis. HISTO is of great value in familial cases, especially in young patients requiring long-term follow-up.
Collapse
Affiliation(s)
- Jing Zhang
- Department of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| | - Kefu Liu
- Department of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
- * Correspondence: Kefu Liu, Department of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, No.242, GuangJi Road, Suzhou, Jiangsu 215008, China (e-mail: )
| | - Yan Sun
- Department of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| | - Jiafeng Yu
- Department of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| |
Collapse
|
14
|
Xu L, Guan R, Yu B, Li Y, Liu H, Jiang Y. Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy. Int J Pharm 2022; 625:122136. [PMID: 36029994 DOI: 10.1016/j.ijpharm.2022.122136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 08/03/2022] [Accepted: 08/18/2022] [Indexed: 10/15/2022]
Abstract
Although deferoxamine (DFO) has been approved for the treatment the iron overloaded diseases, its clinical application is impeded by very short circulation time and its relating toxicity. In this work, the fluorene methoxycarbonyl (FMOC) for "albumin hitchhiking" was used to prolong the plasma circulation time of DFO and reduce toxicity. The designed FMOC-PEG-DFO conjugates were found to reversible bind to albumin and gradually release DFO in vivo. Herein, the FMOC-PEG1000-DFO conjugates could increase 30 times the blood circulation time of DFO with the improvement of the iron elimination efficacy. Meanwhile, the conjugates markedly reduced the cytotoxicity of DFO. Taken together, the result demonstrated the FMOC-PEG1000-DFO conjugates could be a potential therapeutic choice for iron-overload-related diseases.
Collapse
Affiliation(s)
- Linyi Xu
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China
| | - Rou Guan
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China
| | - Bohong Yu
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China
| | - Yicheng Li
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China
| | - Hongzhuo Liu
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
| | - Yiguo Jiang
- Suzhou Science & Technology Town Hospital, Gusu School, Nanjing Medical University, Suzhou 215153, China.
| |
Collapse
|
15
|
Wang Y, Rao Q, Li X. Adverse transfusion reactions and what we can do. Expert Rev Hematol 2022; 15:711-726. [PMID: 35950450 DOI: 10.1080/17474086.2022.2112564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 08/09/2022] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Transfusions of blood and blood components have inherent risks and the ensuing adverse reactions. It is very important to understand the adverse reactions of blood transfusion comprehensively for ensuring the safety of any future transfusions. AREAS COVERED According to the time of onset, adverse reactions of blood transfusion are divided into immediate and delayed transfusion reactions. In acute transfusion reactions, timely identification and immediate cessation of transfusion is critical. Vigilance is required to distinguish delayed responses or reactions that present nonspecific signs and symptoms. In this review, we present the progress of mechanism, clinical characteristics and management of commonly encountered transfusion reactions. EXPERT OPINION The incidence of many transfusion-related adverse events is decreasing, but threats to transfusion safety are always emerging. It is particularly important for clinicians and blood transfusion staff to recognize the causes, symptoms, and treatment methods of adverse blood transfusion reactions to improve the safety. In the future, at-risk patients will be better identified and can benefit from more closely matched blood components.
Collapse
Affiliation(s)
- Yajie Wang
- Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Quan Rao
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Xiaofei Li
- Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
16
|
Rostoker G, Lepeytre F, Merzoug M, Griuncelli M, Loridon C, Boulahia G, Cohen Y. Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients. Pharmaceutics 2022; 14:pharmaceutics14071408. [PMID: 35890303 PMCID: PMC9323124 DOI: 10.3390/pharmaceutics14071408] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 06/29/2022] [Accepted: 07/02/2022] [Indexed: 01/31/2023] Open
Abstract
Anemia is a major complication of end-stage kidney disease (ESKD). Erythropoiesis-stimulating agents and intravenous (IV) iron are the current backbone of anemia treatment in ESKD. Iron overload induced by IV iron is a potential clinical problem in dialysis patients. We compared the pharmacokinetics of liver accumulation of iron sucrose, currently used worldwide, with two third-generation IV irons (ferric carboxymaltose and iron isomaltoside). We hypothesized that better pharmacokinetics of newer irons could improve the safety of anemia management in ESKD. Liver iron concentration (LIC) was analyzed in 54 dialysis patients by magnetic resonance imaging under different modalities of iron therapy. LIC increased significantly in patients treated with 1.2 g or 2.4 g IV iron sucrose (p < 0.001, Wilcoxon test), whereas no significant increase was observed in patients treated with ferric carboxymaltose or iron isomaltoside (p > 0.05, Wilcoxon-test). Absolute differences in LIC reached 25 μmol/g in the 1.2 g iron sucrose group compared with only 5 μmol/g in the 1 g ferric carboxymaltose and 1 g iron isomaltoside groups (p < 0.0001, Kruskal−Wallis test). These results suggest the beneficial consequences of using ferric carboxymaltose or iron isomaltoside on liver structure in ESKD due to their pharmacokinetic ability to minimize iron overload.
Collapse
Affiliation(s)
- Guy Rostoker
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
- Collége de Médecine des Hôpitaux de Paris, 75005 Paris, France
- Correspondence: ; Tel.: +33-1-69-39-92-00
| | - Fanny Lepeytre
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Myriam Merzoug
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Mireille Griuncelli
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Christelle Loridon
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Ghada Boulahia
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Yves Cohen
- Division of Radiology, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France;
| |
Collapse
|
17
|
Branisso PPF, de Oliveira CPMS, Filho HML, Lima FR, Santos AS, Mancini MC, de Melo ME, Carrilho FJ, Rocha MDS, Clark P, Branisso HJP, Cercato C. Non-invasive methods for iron overload evaluation in dysmetabolic patients. Ann Hepatol 2022; 27:100707. [PMID: 35477031 DOI: 10.1016/j.aohep.2022.100707] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 03/04/2022] [Accepted: 03/22/2022] [Indexed: 02/04/2023]
Abstract
INTRODUCTION Although hyperferritinemia may reflect the inflammatory status of patients with non-alcoholic fatty liver disease (NAFLD), approximately 33% of hyperferritinemia cases reflect real hepatic iron overload. AIM To evaluate a non-invasive method for assessing mild iron overload in patients with NAFLD using 3T magnetic resonance imaging (MRI) relaxometry, serum hepcidin, and the expression of ferritin subunits. METHODS This cross-sectional study assessed patients with biopsy-proven NAFLD. MRI relaxometry was performed using a 3T scanner in all patients, and the results were compared with iron content determined by liver biopsy. Ferritin, hepcidin, and ferritin subunits were assessed and classified according to ferritin levels and to siderosis identified by liver biopsy. RESULTS A total of 67 patients with NAFLD were included in the study. MRI revealed mild iron overload in all patients (sensitivity, 73.5%; specificity, 70%). For mild (grade 1) siderosis, the transverse relaxation rate (R2*) threshold was 58.9 s-1 and the mean value was 72.5 s-1 (SD, 33.9), while for grades 2/3 it was 88.2 s-1 (SD, 31.9) (p < 0.001). The hepcidin threshold for siderosis was > 30.2 ng/mL (sensitivity, 87%; specificity, 82%). Ferritin H and ferritin L subunits were expressed similarly in patients with NAFLD, regardless of siderosis. There were no significant differences in laboratory test results between the groups, including glucose parameters and liver function tests. CONCLUSIONS MRI relaxometry and serum hepcidin accurately assessed mild iron overload in patients with dysmetabolic iron overload syndrome.
Collapse
Affiliation(s)
- Paula Pessin Fábrega Branisso
- Obesity and metabolic syndrome study group, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil.
| | | | - Hilton Muniz Leão Filho
- Radiology department, InRad, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | - Fabiana Roberto Lima
- Patology department, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | - Aritânia Sousa Santos
- Laboratory of Carbohydrates and Raioimmunoassay (LIM/18), Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | - Marcio Correa Mancini
- Obesity and metabolic syndrome study group, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | - Maria Edna de Melo
- Radiology department, InRad, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | - Flair José Carrilho
- Gastroenterology department, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | - Manoel de Souza Rocha
- Radiology department, InRad, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | - Paul Clark
- Magnepath digital health company, Perth, Australia
| | | | - Cintia Cercato
- Obesity and metabolic syndrome study group, Hospital das Clínicas de São Paulo, HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil
| |
Collapse
|
18
|
Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 2022; 139:3018-3029. [PMID: 34601591 PMCID: PMC11022970 DOI: 10.1182/blood.2021011338] [Citation(s) in RCA: 78] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Accepted: 09/05/2021] [Indexed: 12/15/2022] Open
Abstract
Hemochromatosis (HC) is a genetically heterogeneous disorder in which uncontrolled intestinal iron absorption may lead to progressive iron overload (IO) responsible for disabling and life-threatening complications such as arthritis, diabetes, heart failure, hepatic cirrhosis, and hepatocellular carcinoma. The recent advances in the knowledge of pathophysiology and molecular basis of iron metabolism have highlighted that HC is caused by mutations in at least 5 genes, resulting in insufficient hepcidin production or, rarely, resistance to hepcidin action. This has led to an HC classification based on different molecular subtypes, mainly reflecting successive gene discovery. This scheme was difficult to adopt in clinical practice and therefore needs revision. Here we present recommendations for unambiguous HC classification developed by a working group of the International Society for the Study of Iron in Biology and Medicine (BIOIRON Society), including both clinicians and basic scientists during a meeting in Heidelberg, Germany. We propose to deemphasize the use of the molecular subtype criteria in favor of a classification addressing both clinical issues and molecular complexity. Ferroportin disease (former type 4a) has been excluded because of its distinct phenotype. The novel classification aims to be of practical help whenever a detailed molecular characterization of HC is not readily available.
Collapse
Affiliation(s)
- Domenico Girelli
- Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Fabiana Busti
- Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Pierre Brissot
- INSERM, Univ-Rennes, Institut National de la Recherche Agronomique, Unité Mixte de Recherche 1241, Institut NuMeCan, Rennes, France
| | - Ioav Cabantchik
- Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel
| | - Martina U. Muckenthaler
- Department of Pediatric Oncology, Hematology, and Immunology and Molecular Medicine Partnership Unit, University of Heidelberg, Heidelberg, Germany
- Molecular Medicine Partnership Unit, European Molecular Biology Laboratory, Heidelberg, Germany
- Translational Lung Research Center, German Center for Lung Research, Heidelberg, Germany
- German Centre for Cardiovascular Research, Partner Site Heidelberg, Mannheim, Germany
| | - Graça Porto
- Institute for Molecular and Cell Biology, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Clinical Hematology, Santo António Hospital, Porto University, Porto, Portugal
| | - on behalf of the Nomenclature Committee of the International Society for the Study of Iron in Biology and Medicine (BIOIRON Society)
- Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
- INSERM, Univ-Rennes, Institut National de la Recherche Agronomique, Unité Mixte de Recherche 1241, Institut NuMeCan, Rennes, France
- Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel
- Department of Pediatric Oncology, Hematology, and Immunology and Molecular Medicine Partnership Unit, University of Heidelberg, Heidelberg, Germany
- Molecular Medicine Partnership Unit, European Molecular Biology Laboratory, Heidelberg, Germany
- Translational Lung Research Center, German Center for Lung Research, Heidelberg, Germany
- German Centre for Cardiovascular Research, Partner Site Heidelberg, Mannheim, Germany
- Institute for Molecular and Cell Biology, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Clinical Hematology, Santo António Hospital, Porto University, Porto, Portugal
| |
Collapse
|
19
|
Pecorelli A, Franceschi P, Braccischi L, Izzo F, Renzulli M, Golfieri R. MRI Appearance of Focal Lesions in Liver Iron Overload. Diagnostics (Basel) 2022; 12:diagnostics12040891. [PMID: 35453939 PMCID: PMC9029711 DOI: 10.3390/diagnostics12040891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 03/30/2022] [Accepted: 04/01/2022] [Indexed: 11/16/2022] Open
Abstract
Liver iron overload is defined as an accumulation of the chemical element Fe in the hepatic parenchyma that exceeds the normal storage. When iron accumulates, it can be toxic for the liver by producing inflammation and cell damage. This can potentially lead to cirrhosis and hepatocellular carcinoma, as well as to other liver lesions depending on the underlying condition associated to liver iron overload. The correct assessment of liver iron storage is pivotal to drive the best treatment and prevent complication. Nowadays, magnetic resonance imaging (MRI) is the best non-invasive modality to detect and quantify liver iron overload. However, due to its superparamagnetic properties, iron provides a natural source of contrast enhancement that can make challenging the differential diagnosis between different focal liver lesions (FLLs). To date, a fully comprehensive description of MRI features of liver lesions commonly found in iron-overloaded liver is lacking in the literature. Through an extensive review of the published literature, we aim to summarize the MRI signal intensity and enhancement pattern of the most common FLLs that can occur in liver iron overload.
Collapse
|
20
|
Liu D, Lin C, Liu B, Qi J, Wen H, Tu L, Wei Q, Kong Q, Xie Y, Gu J. Quantification of Fat Metaplasia in the Sacroiliac Joints of Patients With Axial Spondyloarthritis by Chemical Shift-Encoded MRI: A Diagnostic Trial. Front Immunol 2022; 12:811672. [PMID: 35116037 PMCID: PMC8804375 DOI: 10.3389/fimmu.2021.811672] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 12/27/2021] [Indexed: 12/21/2022] Open
Abstract
Objective To study the diagnostic performance of chemical shift-encoded MRI (CSE-MRI) in the diagnosis of axial spondyloarthritis (axSpA). Methods CSE-MRI images were acquired for consecutive patients complaining of back pain as well as healthy volunteers. Proton density fat fraction (PDFF) values were measured independently by two readers. Diagnostic performance of CSE-MRI was analyzed by sensitivity analysis and ROC curve analysis. Logistic regression analysis was employed to investigate the risk factors of extensive fat deposition in the SIJs. Results A total of 52 r-axSpA patients, 37 nr-axSpA patients, 24 non-SpA patients and 34 healthy volunteers were included. Mean PDFF values in the SIJs of patients with r-axSpA and nr-axSpA (72.7% and 64.5%) were significantly higher than non-SpA patients and healthy volunteers (56.0% and 57.6%) (p<0.001). By defining extensive fat deposition in the SIJs as ≥8 ROIs with PDFF values over 70%, its sensitivity and specificity in diagnosing axSpA reached 72.47% and 86.21%%. By joining bone marrow edema (BME) with ≥8 ROIs (PDFF>70%), 22 (24.71%) and 23 (25.84%) more axSpA patients were classified as SIJ MRI (+) by reader 1 and 2, but specificities decreased by 15.52% and 10.34%. Multivariate logistic regression analysis confirmed longer disease duration as the independent risk factor of extensive fat deposition in SIJs (OR=1.15, 95%CI[1.03, 1.32]), while bDMARDs medication was a protective factor (OR=0.15, 95%CI[0.04, 0.51]). Conclusion CSE-MRI is a reliable tool to quantitively assess the fat metaplasia in the SIJs of axSpA patients. Extensive fat deposition in the SIJs could add incremental diagnostic value to BME, but at the cost of decreased specificities.
Collapse
Affiliation(s)
- Dong Liu
- Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Churong Lin
- Radiology Department, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Budian Liu
- Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Jun Qi
- Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Huiquan Wen
- Radiology Department, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Liudan Tu
- Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Qiujing Wei
- Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Qingcong Kong
- Radiology Department, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Ya Xie
- Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Jieruo Gu
- Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
- *Correspondence: Jieruo Gu,
| |
Collapse
|
21
|
Alessandrino F, Cantisani V. Acoustic radiation force impulse elastography for liver iron overload in β-thalassemia major: Is it going to cut it? JOURNAL OF CLINICAL ULTRASOUND : JCU 2022; 50:117-118. [PMID: 35043443 DOI: 10.1002/jcu.23104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 11/22/2021] [Accepted: 11/22/2021] [Indexed: 06/14/2023]
Affiliation(s)
| | - Vito Cantisani
- Department of Radiological, Oncological, and Pathological Sciences, Faculty of Medicine, Sapienza University of Rome, Rome, Italy
| |
Collapse
|
22
|
Martí-Aguado D, Jiménez-Pastor A, Alberich-Bayarri Á, Rodríguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallén-Peris A, Valero-Pérez E, Ballester MP, Gimeno-Torres M, Pérez-Girbés A, Benlloch S, Pérez-Rojas J, Puglia V, Ferrández A, Aguilera V, Escudero-García D, Serra MA, Martí-Bonmatí L. Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease. Radiology 2021; 302:345-354. [PMID: 34783592 DOI: 10.1148/radiol.2021211027] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Background Standardized manual region of interest (ROI) sampling strategies for hepatic MRI steatosis and iron quantification are time consuming, with variable results. Purpose To evaluate the performance of automatic MRI whole-liver segmentation (WLS) for proton density fat fraction (PDFF) and iron estimation (transverse relaxometry [R2*]) versus manual ROI, with liver biopsy as the reference standard. Materials and Methods This prospective, cross-sectional, multicenter study recruited participants with chronic liver disease who underwent liver biopsy and chemical shift-encoded 3.0-T MRI between January 2017 and January 2021. Biopsy evaluation included histologic grading and digital pathology. MRI liver sampling strategies included manual ROI (two observers) and automatic whole-liver (deep learning algorithm) segmentation for PDFF- and R2*-derived measurements. Agreements between segmentation methods were measured using intraclass correlation coefficients (ICCs), and biases were evaluated using Bland-Altman analyses. Linear regression analyses were performed to determine the correlation between measurements and digital pathology. Results A total of 165 participants were included (mean age ± standard deviation, 55 years ± 12; 96 women; 101 of 165 participants [61%] with nonalcoholic fatty liver disease). Agreements between mean measurements were excellent, with ICCs of 0.98 for both PDFF and R2*. The median bias was 0.5% (interquartile range, -0.4% to 1.2%) for PDFF and 2.7 sec-1 (interquartile range, 0.2-5.3 sec-1) for R2* (P < .001 for both). Margins of error were lower for WLS than ROI-derived parameters (-0.03% for PDFF and -0.3 sec-1 for R2*). ROI and WLS showed similar performance for steatosis (ROI AUC, 0.96; WLS AUC, 0.97; P = .53) and iron overload (ROI AUC, 0.85; WLS AUC, 0.83; P = .09). Correlations with digital pathology were high (P < .001) between the fat ratio and PDFF (ROI r = 0.89; WLS r = 0.90) and moderate (P < .001) between the iron ratio and R2* (ROI r = 0.65; WLS r = 0.64). Conclusion Proton density fat fraction and transverse relaxometry measurements derived from MRI automatic whole-liver segmentation (WLS) were accurate for steatosis and iron grading in chronic liver disease and correlated with digital pathology. Automated WLS estimations were higher, with a lower margin of error than manual region of interest estimations. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Moura Cunha and Fowler in this issue.
Collapse
Affiliation(s)
- David Martí-Aguado
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Ana Jiménez-Pastor
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Ángel Alberich-Bayarri
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Alejandro Rodríguez-Ortega
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Clara Alfaro-Cervello
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Claudia Mestre-Alagarda
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Mónica Bauza
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Ana Gallén-Peris
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Elena Valero-Pérez
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - María Pilar Ballester
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Marta Gimeno-Torres
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Alexandre Pérez-Girbés
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Salvador Benlloch
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Judith Pérez-Rojas
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Víctor Puglia
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Antonio Ferrández
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Victoria Aguilera
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Desamparados Escudero-García
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Miguel A Serra
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| | - Luis Martí-Bonmatí
- From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.)
| |
Collapse
|
23
|
França M. Editorial for "Limits of Fat Quantification With Chemical Shift Encoded". J Magn Reson Imaging 2021; 54:1175-1176. [PMID: 33876877 DOI: 10.1002/jmri.27643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Accepted: 03/31/2021] [Indexed: 11/08/2022] Open
Affiliation(s)
- Manuela França
- Radiology Department, Centro Hospitalar Universitário do Porto, Largo Prof Abel Salazar, Porto, Portugal.,Instituto de Ciências Biomédicas de Abel Salazar, University of Porto, Porto, Portugal.,i3S-Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal
| |
Collapse
|
24
|
Marri UK, Madhusudhan KS. Perivenous Hepatic Iron Deposition in Chronic Liver Disease: MRI Appearance. J Clin Exp Hepatol 2021; 11:628-629. [PMID: 34511826 PMCID: PMC8414312 DOI: 10.1016/j.jceh.2021.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 04/10/2021] [Indexed: 12/12/2022] Open
|
25
|
Marti-Aguado D, Rodríguez-Ortega A, Alberich-Bayarri A, Marti-Bonmati L. Magnetic Resonance imaging analysis of liver fibrosis and inflammation: overwhelming gray zones restrict clinical use. Abdom Radiol (NY) 2020; 45:3557-3568. [PMID: 32857259 DOI: 10.1007/s00261-020-02713-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 07/30/2020] [Accepted: 08/18/2020] [Indexed: 12/13/2022]
Abstract
Magnetic resonance (MR) identification and grading of subjects with liver fibrosis and inflammation represents a clinical challenge. MR elastography plays a well-defined role in fibrosis estimation, but its use is not widely available in clinical settings. Given that liver MR is becoming the reference standard for fat and iron quantitation, there is a need to clarify whether there is any role for MR imaging in the concomitant evaluation of fibrosis and inflammation in this setting. This review summarizes the diagnostic estimations of different MR imaging parameters obtained from conventional non-contrast-enhanced multiple b values diffusion-weighted acquisitions, variable flip angles T1 relaxation maps and STIR images. Although some derived parameters have shown a significant correlation to histological scores, a small magnitude of effect with wide overlap across severity grades is the rule. Contrary to fat and iron quantification, the low precision and reproducibility of MR imaging metrics limits its clinical relevance in fibrosis and inflammation assessment. In a sequential clinical approach combining different methodologies, MR imaging has no applicability for ruling-out and low accuracy for ruling-in advanced fibrosis. Thereby, MR elastography remains as the only image method with high diagnostic accuracy for the detection of advanced fibrosis. Until date, inflammation remains in a gray zone where biopsy cannot be replaced, and further investigations are needed. The present review offers an in-depth discuss of the MR imaging diagnostic performance for the evaluation of liver fibrosis and inflammation, highlighting the need for scientific improvements.
Collapse
Affiliation(s)
- D Marti-Aguado
- Department of Gastroenterology and Hepatology, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
- Biomedical Imaging Research Group (GIBI230 and PREBI), and Imaging La Fe Node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), La Fe Health Research Institute, Valencia, Spain
| | - A Rodríguez-Ortega
- Biomedical Imaging Research Group (GIBI230 and PREBI), and Imaging La Fe Node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), La Fe Health Research Institute, Valencia, Spain
| | - A Alberich-Bayarri
- Biomedical Imaging Research Group (GIBI230 and PREBI), and Imaging La Fe Node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), La Fe Health Research Institute, Valencia, Spain
- Quantitative Imaging Biomarkers in Medicine, QUIBIM SL, Valencia, Spain
| | - L Marti-Bonmati
- Biomedical Imaging Research Group (GIBI230 and PREBI), and Imaging La Fe Node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), La Fe Health Research Institute, Valencia, Spain.
- Radiology Department, La Fe University and Polytechnic Hospital, Av Fernando Abril Martorell 106, 46026, Valencia, Spain.
| |
Collapse
|